Comparative Evaluation of Different Chitosan Species and Derivatives as Candidate Biomaterials for Oxygen-Loaded Nanodroplet Formulations to Treat Chronic Wounds.


Journal

Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729

Informations de publication

Date de publication:
15 Feb 2021
Historique:
received: 15 01 2021
revised: 08 02 2021
accepted: 11 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 21 5 2021
Statut: epublish

Résumé

Persistent hypoxia is a main clinical feature of chronic wounds. Intriguingly, oxygen-loaded nanodroplets (OLNDs), filled with oxygen-solving 2H,3H-decafluoropentane and shelled with polysaccharides, have been proposed as a promising tool to counteract hypoxia by releasing a clinically relevant oxygen amount in a time-sustained manner. Here, four different types of chitosan (low or medium weight (LW or MW), glycol-(G-), and methylglycol-(MG-) chitosan) were compared as candidate biopolymers for shell manufacturing. The aim of the work was to design OLND formulations with optimized physico-chemical characteristics, efficacy in oxygen release, and biocompatibility. All OLND formulations displayed spherical morphology, cationic surfaces, ≤500 nm diameters (with LW chitosan-shelled OLNDs being the smallest), high stability, good oxygen encapsulation efficiency, and prolonged oxygen release kinetics. Upon cellular internalization, LW, MW, and G-chitosan-shelled nanodroplets did not significantly affect the viability, health, or metabolic activity of human keratinocytes (HaCaT cell line). On the contrary, MG-chitosan-shelled nanodroplets showed very poor biocompatibility. Combining the physico-chemical and the biological results obtained, LW chitosan emerges as the best candidate biopolymer for future OLND application as a skin device to treat chronic wounds.

Identifiants

pubmed: 33672056
pii: md19020112
doi: 10.3390/md19020112
pmc: PMC7919482
pii:
doi:

Substances chimiques

Biocompatible Materials 0
Chitosan 9012-76-4
Oxygen S88TT14065

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondazione Cariplo
ID : HyWonNa project, grant no. 2015-0550
Organisme : Compagnia di San Paolo
ID : Torino_call2014_L2_207
Organisme : Università degli Studi di Torino
ID : ex 60%

Références

Toxicol Appl Pharmacol. 2015 Nov 1;288(3):330-8
pubmed: 26276311
J Control Release. 2014 Aug 10;187:101-17
pubmed: 24878179
Biomacromolecules. 2010 Aug 9;11(8):1897-908
pubmed: 20590156
Skin Pharmacol Physiol. 2010;23(3):117-23
pubmed: 20051712
Int J Nanomedicine. 2020 Dec 03;15:9717-9743
pubmed: 33299313
Eur J Med Chem. 2014 Mar 3;74:169-78
pubmed: 24462847
Biomolecules. 2019 Dec 30;10(1):
pubmed: 31905975
IET Nanobiotechnol. 2019 Oct;13(8):778-785
pubmed: 31625517
Int J Pharm. 2008 Apr 2;353(1-2):139-48
pubmed: 18164151
Am Fam Physician. 2020 Feb 1;101(3):159-166
pubmed: 32003952
J Cell Biol. 1988 Mar;106(3):761-71
pubmed: 2450098
J Wound Care. 2015 Feb;24(2):53-4, 56-60, 62-3
pubmed: 25647433
Int J Pharm. 2009 Aug 13;378(1-2):215-7
pubmed: 19501639
Curr Opin Pharmacol. 2020 Aug;53:117-125
pubmed: 32979727
Expert Opin Drug Deliv. 2019 Jul;16(7):715-740
pubmed: 31215823
Front Bioeng Biotechnol. 2016 Oct 31;4:82
pubmed: 27843895
J Drug Target. 2019 Dec;27(10):1035-1045
pubmed: 30808239
Microbes Infect. 2012 Apr;14(4):311-6
pubmed: 22133978
Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:2067-70
pubmed: 19163102
Adv Wound Care (New Rochelle). 2020 Jun 2;:
pubmed: 32320364
Surg Clin North Am. 2020 Aug;100(4):681-693
pubmed: 32681869
Adv Drug Deliv Rev. 2019 Jun;146:344-365
pubmed: 29981800
Int J Biol Macromol. 2016 Dec;93(Pt B):1465-1478
pubmed: 27086294
Nano Today. 2017 Aug;15:91-106
pubmed: 29225665
Thyroid. 2016 May;26(5):705-16
pubmed: 26906083
Phys Chem Chem Phys. 2016 Mar 28;18(12):8378-88
pubmed: 26931337
Polymers (Basel). 2018 Feb 22;10(2):
pubmed: 30966247
Curr Pharm Des. 2019;25(15):1682-1693
pubmed: 31269879
Biomaterials. 1998 Aug;19(16):1529-39
pubmed: 9794531
Int J Nanomedicine. 2016 Aug 29;11:4141-55
pubmed: 27621615
Undersea Hyperb Med. 2016 Mar-Apr;43(2):113-22
pubmed: 27265988
Curr Pharm Des. 2017;23(24):3515-3528
pubmed: 28472915
Eur J Pharm Biopharm. 2009 Feb;71(2):257-63
pubmed: 18955137
Methods Mol Biol. 2008;440:15-33
pubmed: 18369934
Pharmacogn Rev. 2016 Jan-Jun;10(19):39-42
pubmed: 27041872
Ther Deliv. 2016;7(2):117-38
pubmed: 26769397
Expert Opin Drug Deliv. 2019 Dec;16(12):1313-1331
pubmed: 31738622
Int J Pharm. 2010 Dec 15;402(1-2):254-7
pubmed: 20888402
Mar Drugs. 2015 Mar 27;13(4):1710-25
pubmed: 25826718
Int Wound J. 2017 Dec;14(6):1276-1289
pubmed: 28799228
Mar Drugs. 2010 Jun 25;8(7):1962-87
pubmed: 20714418
J Colloid Interface Sci. 2003 May 15;261(2):402-10
pubmed: 16256549
Future Microbiol. 2020 Sep;15:1227-1236
pubmed: 33026879
Mar Drugs. 2015 Mar 02;13(3):1133-74
pubmed: 25738328
J Control Release. 2020 Dec 10;328:532-550
pubmed: 32971198
Traffic. 2002 Jul;3(7):443-51
pubmed: 12047552
J Wound Care. 2017 May 1;26(Sup5):S1-S43
pubmed: 28475468
J Nanobiotechnology. 2014 Feb 03;12:5
pubmed: 24491160
Skin Pharmacol Physiol. 2010;23(3):164-70
pubmed: 20110767
Mediators Inflamm. 2015;2015:964838
pubmed: 25878404
Int J Pharm. 2009 Nov 3;381(2):160-5
pubmed: 19616610
PLoS One. 2015 Mar 17;10(3):e0119769
pubmed: 25781463
Int J Pharm. 2017 May 15;523(1):176-188
pubmed: 28330735
J R Soc Interface. 2013 Feb 20;10(82):20120939
pubmed: 23427093
Mol Ther. 2010 Oct;18(10):1787-95
pubmed: 20628361
Pharm Res. 2018 Feb 26;35(4):75
pubmed: 29484487
Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):26-37
pubmed: 30977868
Adv Ther. 2017 Mar;34(3):599-610
pubmed: 28108895
Biosci Biotechnol Biochem. 2016;80(3):466-72
pubmed: 26523859
Int J Mol Sci. 2018 May 14;19(5):
pubmed: 29757956
Int J Pharm. 2020 Sep 25;587:119676
pubmed: 32738458
Adv Wound Care (New Rochelle). 2016 Jul 1;5(7):314-328
pubmed: 27366592
Colloids Surf B Biointerfaces. 2016 Sep 1;145:201-207
pubmed: 27182655
Adv Wound Care (New Rochelle). 2014 May 1;3(5):390-399
pubmed: 24804159
Wounds. 2016 Aug;28(8):264-70
pubmed: 27560469
Future Microbiol. 2015;10(6):929-39
pubmed: 26059617
Eur J Pharm Biopharm. 2016 Mar;100:101-8
pubmed: 26792104
Int J Mol Sci. 2016 Dec 11;17(12):
pubmed: 27973441
Toxicol Appl Pharmacol. 2015 Aug 1;286(3):198-206
pubmed: 25937238
Biomacromolecules. 2008 Jul;9(7):1837-42
pubmed: 18540644
J Invest Dermatol. 2001 Jan;116(1):50-6
pubmed: 11168797
Pharm Dev Technol. 2017 Jun;22(4):458-466
pubmed: 26608060

Auteurs

Monica Argenziano (M)

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.

Bruno Bressan (B)

Department of Neuroscience, University of Turin, 10126 Turin, Italy.
Department of Oncology, University of Turin, 10126 Turin, Italy.

Anna Luganini (A)

Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.

Nicole Finesso (N)

Department of Oncology, University of Turin, 10126 Turin, Italy.

Tullio Genova (T)

Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Adriano Troia (A)

Istituto Nazionale di Ricerca Metrologica (INRIM), 10135 Torino, Italy.

Giuliana Giribaldi (G)

Department of Oncology, University of Turin, 10126 Turin, Italy.

Giuliana Banche (G)

Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.

Narcisa Mandras (N)

Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.

Anna Maria Cuffini (AM)

Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.

Roberta Cavalli (R)

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.

Mauro Prato (M)

Department of Neuroscience, University of Turin, 10126 Turin, Italy.
Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH